Our Take
The rule closes a genuine gap in price protection, but the 2029 timeline gives manufacturers five years to plan—and Congress time to intervene.
Why it matters
Immunotherapy makers have used IV-to-subcutaneous reformulations to reset patent clocks and avoid price negotiation. Closing this loophole expands Medicare's negotiation authority, but the delayed implementation signals political room for pushback from pharma.
Do this week
Compliance leads: audit your IV-to-subcutaneous pipeline timelines against the 2029 effective date so you can model pricing scenarios and regulatory strategy before the rule finalizes.
The rule targets a known workaround
Medicare's proposed rule for 2029 would eliminate a protection that currently shields medicines transitioning from intravenous to subcutaneous administration from price negotiation authority. The change directly affects cancer immunotherapies, including Bristol Myers Squibb's Opdivo and Merck's Keytruda, which have been reformulated or are in development as under-the-skin alternatives to their IV versions.
Under existing rules, drugs that change delivery method are treated as new medications and receive renewed exclusivity periods, insulating them from Medicare price negotiation for several years. The proposed rule classifies such transitions as what the agency describes as a "loophole"—a regulatory gap that allows manufacturers to extend market protection without meaningful clinical innovation.
Five years is a long runway for resistance
The 2029 effective date matters more than the rule itself. Pharma has half a decade to lobby Congress, challenge the rule in court, or accelerate subcutaneous launches before negotiation authority kicks in. The timeline also reflects political calculation: a shorter delay would trigger immediate industry opposition; a longer one admits the rule is winnable.
For Medicare, the rule expands negotiation leverage over a category of drugs that have so far escaped it. Opdivo and Keytruda are blockbusters, and subcutaneous formulations reduce patient friction, so the commercial pressure to maintain exclusivity is high. The rule does not retroactively apply to drugs already approved—it targets future transitions—which limits immediate revenue impact but signals intent to close similar gaps.
Track the rule finalization and congressional calendar
The rule is proposed, not final. Final rulings typically include accommodation for industry comment and can be narrowed or delayed. Watch for two signals: amendments that exempt certain drug classes (oncology drugs are a likely candidate for carve-outs) and legislative riders attached to budget bills or reauthorization packages that delay or block the rule outright.
For companies with subcutaneous programs in development, the 2029 date is a hard deadline only if the rule survives finalization and review. Portfolio strategy should assume the rule holds, but pricing and market-entry decisions should account for Congressional interference risk. The gap between now and 2029 is not dead time; it is negotiation time.